{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:59:01Z","timestamp":1789185541616,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":479,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Ursodeoxycholic acid (UDCA) is the drug of choice for treating primary biliary cirrhosis and dissolving cholesterol gallstones.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p>The objective of this study was to compare the bioavailability of four commercially available ursodeoxycholic acid formulations in standardized doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Twenty\u2010four healthy subjects were studied in groups of four, and received each of the different UDCA preparations in random order, with a 1\u2010week washout or more in\u2010between. Serum UDCA levels were determined for a 6\u2010h period. The mean area under the curve (AUC), <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub> were determined for each drug formulation, and the results compared. Dose proportionality was determined using the Canadian Ursofalk tablet using either 250\u2003mg, 500\u2003mg or 750\u2003mg dosing. The intraparticipant variability was assessed by asking each participant to repeat the last drug that they took the second time, 1 week later.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The mean AUC was 68.99\u2003\u03bcmol\/1.6\u2003h<jats:sup>\u22121<\/jats:sup> for the USA UDCA tablet, 59.34\u2003\u03bcmol\/1.6\u2003h<jats:sup>\u22121<\/jats:sup> for the Canadian UDCA tablet, 55.55\u2003\u03bcmol\/1.6\u2003h<jats:sup>\u22121<\/jats:sup> for Ursolvan capsules, and 46.66\u2003\u03bcmol\/1.6\u2003h<jats:sup>\u22121<\/jats:sup> for Actigall capsules. The mean <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> values were 24.29, 17.85, 16.63 and 413.32\u2003nmol\/mL, respectively. The mean <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub> was 1.82, 2.3, 2.79 and 3.39\u2003h, respectively. Linear aggression analysis assessing the direct proportionality of AUC on the dose for the Canadian UDCA tablet gave an estimate of 0.063\u2003+\u20030.0164 (standard error, <jats:italic>P<\/jats:italic>\u2010value=0.0117), e.g. if the dose increases from 250\u2003mg to 500\u2003mg, the serum ursodeoxycholic acid increases by 250\u2003\u00d7\u20030.063=15.75. There was excellent reproducibility for the AUC for the North American tablets (0.97, 0.88) compared to the two capsules (0.32, 0.15).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The significantly higher AUC and <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and shorter <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub> for the Canadian Ursofalk tablets compared to the UDCA capsule preparations supports better bioavailability.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00817.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:42:16Z","timestamp":1047354136000},"page":"1133-1139","source":"Crossref","is-referenced-by-count":17,"title":["Bioavailability of four ursodeoxycholic acid preparations"],"prefix":"10.1111","volume":"14","author":[{"family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Al\u2010Knawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(83)90695-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(81)90011-4"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190512"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(89)90140-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(69)90321-0"},{"key":"e_1_2_6_7_2","unstructured":"WilliamsCN MorseJWI MacDonaldIA KatoorR RidingMD.Increased lithogenicity of bile on fasting normal subjects.Am J Dig Dis1977:18994."},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-2275(20)39818-7","article-title":"3\u03b1\u2010, 7\u03b1\u2010, and 12\u03b1\u2010OH group specific enzymatic analysis of biliary bile salts: comparison with gas chromatography","volume":"21","author":"MacDonald IA","year":"1980","journal-title":"J Lipid Res"},{"key":"e_1_2_6_9_2","first-page":"29","article-title":"Primary bile acid kinetics in patients with primary biliary cirrhosis","volume":"2","author":"Williams CN","year":"1979","journal-title":"Clin Invest Med"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01308414"},{"key":"e_1_2_6_11_2","unstructured":"JonesB&KenwardMG. In Design and Analysis of Crossover Trials. New York NY: Chapman & Hall 1989."},{"key":"e_1_2_6_12_2","unstructured":"CohenJ. Statistical Power Analysis for the Behavioral Sciences 2nd edn. Hillsdale New Jersey: Lawrence Erlbaum Associates 1988."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529409103618"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/1043-6618(95)80056-5"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1985.tb00164.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01324946"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1983.tb00126.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/1043-6618(95)80019-0"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00817.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00817.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00817.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:47:47Z","timestamp":1697395667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00817.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00817.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00817.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}